Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I will have a look pal but the mrs is on my case for having too much in shares :(
I was there and apologies for the delay in me posting a few comments. Products are seen as premium products and are priced accordingly. Whereas many, many years ago 5% active ingredient in Deet was sufficient to be effective , now more like 50% is needed. The focus of the company is to concentrate on selling the head life treatment initially , and contracts are established with big retailers including Walmart . Negotiations are on going with big retailers here including major supermarkets. Our products are MUCH more customer friendly to use - am sure anyone who has used these products will agree. Insects almost certainly can't build up resistance to the treatment as it attacks 4 'receptors' - and should resistance be detected , then the formula can easily be changed. The regulatory environment is very ' light touch ' 50 mill $ ( £ ) ? has been spent on development !!! I asked whether there was any large advertising campaign planned , and if so , wouldn't that be hugely expensive ? Answer - Because of the particular socially active environment within which this product would be used I.E . schools there would be serious communication via Twitter and Facebook which would act as 'free advertising ' - Interesting concept !!!! Regarding funding - there were comments that , that may ? ? be available from Walmart. A series of independent tests at a number of accredited testing facilities have all come up with very impressive results - - being superior to the competition - which , as mentioned is losing its effectiveness anyway. Tere are a number of products under development - not sure how advanced they all are . The one which I personally think could be mega mega is the mosquito repellent - more effective and longer lasting than Deet based products and MUCH more pleasant to use - I assume that we have all been through the the unpleasant experience of using the existing deterrents. There must be an absolutely MASSIVE market for such a potentially AWESOME product. !!!!!!!! There are other potential major money spinners , including a treatment for animals and pets . Back to the head lice treatment - I was very pleased to note that alongside the treatment product , a preventative shapoo is to be sold too . Imagine what the potential will be in very health conscious countries for mums to keep to be given the opportunity of keeping little Johnny or Joanne free from any danger from those unhygienic little rascals. Good points , Fantastic product IMO , tiny market cap , decent director holdings , excellent test results, potentially almost limitless demand , contracts agreed with major potential outlets, good development technical team (I am told ) , high cost / difficulties for any potential competitors , cheap share price. There is considerable annoyance over the low share price - and on reflection I agree with that one. !! The low share price is partly put down to some bad publicity over a business problem in another
aAll comments welcomed when they arrive.
http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11733318 The Company received notification on 4 October 2013 that, Alan Reade, Non-Executive Chairman of the Company, purchased on that date 675,000 common shares of US$0.001 in the Company ("Common Shares") at a price of 5 pence per share. 227,000 of the Common Shares purchased were purchased in Alan Reade's wife's name. Following this transaction, Alan Reade is beneficially interested in 10,486,358 Common Shares representing an interest of 6.25 per cent of the total voting rights of the Company. In addition, Alan Reade is interested in 2,645,695 stock appreciation right options over Common Shares as follows: Options Held Option Exercise Price Expiry Date 1,000,000 6p 25 April 2022 100,570 12p 6 March 2022 550,000 10.5p 4 February 2020 995,125 12p 20 October 2020
I was there - and had an hour chat with Andy afterwards will post some comments when I can .On the train a lot tomorrow so will comment when I can.
A major step forward for Tyratech's head lice formulae. In tests carried out in Germany it proves to be more effective in killing lice than the current German brand leader. The product has been granted regulatory approval for sale in Germany . as ever DYOR
TyraTech, Inc. (AIM: TYR and TYRU), a natural life sciences company, is pleased to announce that the Company has received notification from the U.K. regulatory body, the Medicines and Healthcare products Regulatory Agency ('MHRA'), that the Company's head lice product VaMOUSSE!™ has been registered with the MHRA as a Class I medical device. As a Class I medical device, VaMOUSSE!™ will be subject to the lowest level of regulatory oversight. Expected product to be launched in the first half of 2013 Great news today. Looks like this will be the best head lice treatment on the market by far. Very glad to be invested here,
Positive news for the head lice formulae,,.British regulatory acceptance. The next hurdle is to decide whether to market and sell the product themselves or appoint a distributor for the uk. To soon to say but maybe next year that ugly capatalistic thing called profits may be on the horizon. As ever DYOR but this share is starting to be exciting.
With a market cap of only 6 million,it wouldn't take a lot of news to trigger a sharp rise in the sp.Can't imagine anyone wanting to sell''.
trade just gone through,not showing on l2...
New TyraTech Investor Presentation - 22nd November 2012 (PDF) out at proactiveinvestors Under Related Media Section Loads happening soon including: Retail launch at The Home Depot to begin in Q1 2013 Head lice Product currently under US regulatory review; Product launch expected in 2013 Cash Balance: (June 2012) $2.1 million Debt: nil
TyraTech enjoyed a bounce after announcing its new insect repellent had been granted registration in the US, leaving it just one step short of being on the shelves.
A very nice SP reaction today - all good since Sept
TyraTech's Vice President of Commercial Operations, Shayne Wetherall, added: "NO-SKEETO!™ provides a compelling and timely solution for families seeking superior non-toxic protection. This product also provides TyraTech with outstanding commercial opportunities as it is ready for immediate commercialisation. We are currently in the process of evaluating global commercial and retail partners for this product and for our strong pipeline of personal repellent solutions".
Great news. Maybe now a share to be buying back into? As ever DYOR This looks like the start of a rerating of the share price upwards. There is still a possibility of a cash call . However, the potential income from licensing of the no skeets formulae is massive. Ongoing annual income stream from a product that is more effective than Deet. Huge huge business opportunity.Sorry if this sounds like a ramp, it isnt, but it is. 1
As I said; Worth a punt ;)
Worth a punt IMO.
any views on this company guys?
STRATEGY & OUTLOOK Given the many advances the Company has made in its product development pipeline, licensing discussions and product commercialization efforts over the past three months in particular, the Board continues to be optimistic with regard to the Company's prospects. The Board believes that the launch of the Company's consumer insect control products in The Home Depot will be a significant catalyst for future growth of the Company, and further discussions with other potential partners continue to progress well. However, there is always uncertainty as to the timing and amounts of any resulting funds from prospective licensing agreements, and although we believe that existing and anticipated cash resources may be sufficient for the short-term, we consider that it would be prudent and in shareholders' interests to now seek additional funding, either through debt or equity financing, to support general and working capital needs.
Alan Reade, Executive Chairman of TyraTech commented: "We are pleased to have announced within the last few days our Trademark License Agreement with Terminix and the launch in early 2013 of our products at The Home Depot in the U.S., the world's largest home improvement retailer. We believe that this will be a significant catalyst for the future growth of TyraTech, and re-enforces our optimism for the Company's short and medium-term prospects. Other out-licensing and partnering discussions are also progressing well, but in order to help deliver this potential, we believe it would be in shareholders' interests to raise additional financing in the near future, which could be by way of debt or equity."
Financial Highlights: · Cash and cash equivalents of US$2.1 million at 30 June 2012 (US$1.6 million at 30 June 2011 and US$0.9 million at 31 December 2011); · Raised US$3.8 million in capital in February 2012, net of expenses, through the issuance of 52,101,460 common shares; · Total revenues from continuing operations decreased to US$0.4 million (2011: US$5.0 million) as a result of decreased sales to our largest customer; · Gross profit decreased to US$0.3 million (2011: $3.5 million); · Overall operating expenses decreased to US$3.2 million (2011: US$4.1 million); and · Loss increased to US$2.8 million for the first half of 2012 (2011: US$0.5 million net loss). To help maximize the potential value to shareholders that would be captured by successfully concluding ongoing negotiations with commercial partners, to ensure the Company's working capital position, and, potentially, also to fund the increased capital requirements of the business associated with production of leading product lines, the Board believes that the Company should plan to raise additional funding. A number of discussions are taking place and further announcements will be made as appropriate.
Interim Results for the six months ended 30 June 2012 TyraTech, Inc. ("the Company") (AIM: TYR and TYRU), a natural life sciences company that harnesses the power of nature to improve human and animal health using a proprietary, novel technology that is both effective against insects and parasites and safe for people and pets, today announces its interim operating and financial results for the six month period ended 30 June 2012 and other post period operating events. Operational Highlights: · Entered into a Trademark License Agreement with Terminix which licenses the use of the Terminix brand to TyraTech for sales of the Company's insect control products, opening the U.S. consumer market for the Company; · Reached agreement with The Home Depot for the 2013 U.S. launch of the Company's new line of consumer insect control products utilizing the Terminix brand; · Successful development of a floor and surface repellent product resulting in a near-term opportunity to conclude an agreement with a major fast-moving consumer goods ("FMCG") group and medium to longer term discussions with the same party on a prospective global license for household pesticides; · Submission of the Company's regulatory package for a head lice removal kit to the U.S. Food and Drug Administration ("F.D.A.") and the U.K. Medicines and Healthcare products Regulatory Agency ("M.H.R.A."); · Completion of a human clinical study of a natural formulation for head lice showing greater effectiveness than the current synthetic based market leader which the Company believes will form the basis for further products; and · Development of a personal insect repellant and submission of regulatory packages to authorities with expected product launch in the first half of 2013.
http://www.investegate.co.uk/Article.aspx?id=201210010700085272N
Interesting results today. Their technology is enabling fast dev elopment of product in many different commercially viable areas, The effect of Terminix withdrawing their orders earlier this year was a huge blow to Tyratech. It now appears they have a wide range of products that are being developed or are already in existence in readiness for retail sales. Good news. The part that interests me more is the results from testing their product on various creepy crawlies that affect human and animal health in particular the tests on mosquito repellant,.. All they have to do now is to generate income. Institutional investors have been very supportive and have funded the continuing research and development. Earlier this year this company was a basket case with little hope. Maybe we as smaller investors have a chance of a great return on our investment. Always DYOR and try and invest wisely